Abstract: An image processing apparatus includes a placement unit that is provided on an upper surface of a housing and on which a document is placed; an imaging unit that images the placement unit from above; and a processor configured to display guidance information indicating that the document to be imaged by the imaging unit is to be placed on the placement unit, on a display unit.

Abstract: A process for preparing a coated composition comprising a pharmaceutically active substance stable to heat, which comprises centrifugally granualting a mixture comprising said active substance and a first thermomelting material as a binder under heating without using any solvent and coating the resultant granules with a second thermomelting material as a coating material under heating, the melting point of the second thermomelting material being lower than that of the first thermomelting material.

Abstract: A favorable sustained-releasing property is given to granular preparations by incorporating therein at least one C.sub.16 -C.sub.18 saturated fatty acid and/or metal salts thereof at a rate of 10-50% of the total weight of the dosage form. The disclosed dosage form releases the active ingredient both in a low pH region of the stomach and in a high pH region of the intestine at an appropriate rate.

Abstract: Suppository containing a one-to-one complex of sulfamethoxazole and trimethoprim dispersed in a pharmaceutically acceptable carrier is disclosed. It may contain a supplemental amount of sulfamethoxazole in addition to the sulfamethoxazole component in the complex and is superior to conventional preparations of a simple mixture in its manufacturing process as well as its pharmacokinetical property.

Abstract: The invention provides a novel means for the administration of a therapeutically effective ingredient in the form of a rectally applicable medicament capsule, in which the otherwise unavoidable extreme variation in the absorbability of the effective ingredient among the individuals rectally treated with the capsules is minimized. It has been unexpectedly found that, when the effective ingredient is contained in the capsule in the form of a liquid medicine, the osmotic pressure of the liquid content plays a very essential role in the absorption of the effective ingredient through the rectum and the variation in the absorbability of the effective ingredient among the individuals can be minimized when the osmotic pressure of the liquid content is substantially higher than the osmotic pressure of the rectal fluid with which the capsules are contacted.

Abstract: The invention provides a novel and efficient means for the administration of a therapeutically effective ingredient by rectal application in the form of a medicament capsule encapsulating the effective ingredient. The medicament capsule according to the invention is formed of a hard capsule shell made of a mixed ester of a cellulose ether, e.g. alkyl-, hydroxyalkyl- and hydroxyalkyl alkylcelluloses, esterified with aliphatic monacyl groups and acidic succinyl groups. When the capsule is inserted into the rectum, the capsule shell is disintegrated and the rectally absorbable effective ingredient is readily and smoothly released into the rectum and absorbed to exhibit therapeutical effects as efficiently as with conventional suppositories.

Abstract: The invention provides a novel means for overcoming the problem of undue and irregular delay in the exhibition of the effect of medicine when a patient is administrated with an enterosoluble hard-capsulated medicament. The unexpected discovery that the key parameter ruling the smooth transfer of an enterosoluble capsule from the stomach to the intestinal canals is the overall specific gravity of the capsule has led to the establishment of the invention which proposes an enterosoluble hard-capsulated medicament having an overall specific gravity of at least 1.05 or, preferably, at least 1.10.

Abstract: The invention provides a novel means for overcoming the problem of undue and irregular delay in the exhibition of the effect of medicine when a patient is administrated with an enterosoluble hard-capsulated medicament. The unexpected discovery that the key parameter ruling the smooth transfer of an enterosoluble capsule from the stomach to the intestinal canals is the overall specific gravity of the capsule has led to the establishment of the invention which proposes an enterosoluble hard-capsulated medicament having an overall specific gravity of at least 1.05 or, preferably, at least 1.10.

Abstract: A cefalexin preparation coated with a coating layer the solubility of which layer is pH-dependent and dissolves in the upper intestine is preferably administered concurrently with a normal (plain, quick-releasing) cefalexin. The coated preparation is preferably coated, in the particle form and when administered orally, exists in the particle form in the stomach. Preferably, the coating layer is made from a coating material having a dissolution pH of from 5.5 to 6.5, and the ratio in terms of potency of the coated cefalexin to the normal cefalexin is between 15:85 and 60:40. The coated cefalexin and the normal cefalexin can be formulated in a pharmaceutical preparation preferably in a unit-dosage form, e.g., capsules, tablets or particles or in strip-packages.